02.05.26 -- What To Watch For In The 2026 Clinical Trial Landscape

Modeling and simulation provides another way to predict the clinical performance of a molecule, based on a robust and holistic approach, before investing the required time and money.

Tech transfer is not just a process of replicating manufacturing steps; it is a complex, multidisciplinary effort that ensures process robustness, scalability, regulatory compliance, and supply chain readiness.

Move drug development into the modern era with a CRO that offers assay development and validation, bioanalytical testing, sample prep, and more.

Partnering with Southern Star Research provides access to deep regional expertise, operational excellence, and a proven track record of delivering high-quality clinical trials.

When a country hosts a clinical trial, we assume patients there will benefit from the therapy they helped test. Research Jennifer E. Miller, Ph.D., says that's not often the case.

Explore how AI integration, remote assessment, and precision measurement are reshaping clinical trials in 2026 to improve data quality and patient outcomes.

Examine the complex regulatory landscape and the preclinical, clinical, and manufacturing challenges involved in developing Schedule 1 therapeutics.

Navigating the Clinical Trial Registry Ecosystem — Regional and Global Registry Selection provides harmonization initiatives to improve transparency and data consistency across registries.

Emerging psychiatric therapies bring hope, but progress is fragile. Biomarker-driven, mechanism-first approaches help overcome biological, regulatory, and commercial barriers.

Whether it’s accelerating market entry with the “FSP Country in a Box” solution or maintaining global compliance through expert oversight, IQVIA empowers organizations with scalable, localized support.